Login to Your Account

Phase III To Start This Year

Affymax Clearing Pathway For Hematide In 'Murky' ESA Space

By Jennifer Boggs

Tuesday, July 17, 2007
In the midst of increased regulatory scrutiny involving erythropoiesis-stimulating agents (ESAs), Affymax Inc. is forging ahead with a Phase III program of its anemia drug, Hematide, in chronic renal failure patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription